McDermott Advises Diabeloop on New Series C Financing Round - McDermott Will & Emery

McDermott Advises Diabeloop on New Series C Financing Round


McDermott Will & Emery advised Diabeloop, a Grenoble-based artificial intelligence company specialising in the treatment of diabetes, on its Series C financing round – led by LBO France, joined by Terumo Corporation, Innovacom and backed by Diabeloop’s long standing partners – to power the company’s commercial roll-out and global expansion.

This is the third round of financing for Diabeloop.

This round of financing will enable Diabeloop to continue the development of its DBLG1 algorithm, which is hosted in a dedicated terminal that serves as a user interface with the system, associated with a continuous glucose sensor (CGM) and an insulin pump.

The McDermott team comprised:

  • Fabrice Piollet, partner, Marie-Muriel Barthelet, counsel and Alexandre Bomet, associate, on the corporate aspects;
  • Anne-France Moreau, partner, and Lucie Martin, associate, on the life sciences aspects;
  • Antoine Vergnat, partner, and Côme de Saint-Vincent, counsel, on tax aspects

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.